BACK TO CONTENTS   |    PDF   |    PREVIOUS   |    NEXT

Title

Computational finding of potential inhibitor for Cytochrome P450 Mono-oxygenases Enzyme of Mycobacterium tuberculosis

 

Authors

Ashwani Sharma1*, Krishna K Subbias2$, Ophélie Robine3$, Indu Chaturvedi4$, Anshul Nigam1, 5$, Nishant Sharma6, Prem Prashant Chaudhary7$

 

Affiliation

1Center of drug discovery research, New Era Proteomics, C-1/31, Yamuna Vihar, New Delhi-110053, India; 2Department of Chemical Engineering, Indian Institute of Technology Bombay, Mumbai – 400076, India; 3Mass Spectrometry center, New Era Proteomics, 83 route de Grimard, 33670 Créon, France; 4Department of Animal Nutrition, Central Institute of Research on Goats (C.I.R.G.), Makhdoom, Farah, Mathura, UP-281122, India; 5Interdisciplinary Programme in Life Science, Pondicherry University,Puducherry-605014 India; 6Institute of Human Behaviour & Allied Sciences (IHBAS), Jhilmil, Dilshad Garden Delhi-110095, India; 7Biowits Life Sciences, Computational Biology Section, Yamuna Nagar-135001 ,Haryana, India

 

Email

ashwansharma@gmail.com; *Corresponding author

 

Article Type

Hypothesis

 

Date

Received September 15, 2012; Accepted September 19, 2012; Published October 01, 2012

 

Abstract

Cytochrome P450 mono-oxygenases (2UUQ) enzyme from Mycobacterium tuberculosis catalyzes oxidation of organic compounds such as lipids and steroidal hormones therefore remain as potential drug target. Currently available first line anti-tuberculosis drugs have been caused several side effects in the body as well as resistance development by mycobacterium against these drugs, necessitates the considerable need for finding new drugs. Therefore, we propose a structure based computational method to find a new potential inhibitor for cytochrome P450 mono-oxygenases enzyme. Compounds from several ligand databases were docked against the functional sites of 2UUQ (A) through the standard GEMDOCK v2.0 and AUTODOCK4.0 molecular docking tools. Commercially available chemical compound ZINC00004165 (5-[3-(2-nitroimidazol-1-yl) propyl] phenanthridine) has produced top rank with lowest interaction energy of -113.2 (via GEMDOCK) and lowest docking energy of -9.80 kcal/mol (via AUTODOCK) as compared to first line anti TB compounds. Z score and normal distribution analysis verified that the ZINC00004165 compound has more affinity towards 2UUQ in comparison to large number of random population of compounds. ZINC00004165 is also in agreement with the drug likeness properties of Lipinski rule of five without any violation. Therefore, our finding concludes that the commercial compound ZINC00004165 can act as a potential inhibitor against cytochrome P450 mono-oxygenases enzyme of Mycobacterium tuberculosis.

 

Keywords

Cytochrome P450 mono-oxygenases, Tuberculosis, Ligand database, Docking, Gemdock, Autodock

 

Citation

Sharma et al. Bioinformation 8(19): 931-937 (2012)
 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

Copyright

Publisher

 

Copyright Transfer Agreement

The authors of published articles in Bioinformation automatically transfer the copyright to the publisher upon formal acceptance. However, the authors reserve right to use the information contained in the article for non commercial purposes.

 

License

This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original author and source are credited.